We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Edge Therapeutics, Inc. (NASDAQGS: EDGE) to PDS Biotechnology Corporation (“PDS”). The transaction is structured as a stock-for-stock transaction; upon completion of the transaction, Edge Therapeutics shareholders will own 30% of the combined company.
The Edge Therapeutics merger investigation concerns whether the Board of Edge Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether PDS is underpaying for Edge Therapeutics shares, thus unlawfully harming Edge Therapeutics shareholders.
To receive more information, please fill out the form.